ArticlePharmacology research & perspectives2025
Carbohydrate-Rich Fraction of Aloe vera (L.) Burm.f. Extract Mitigates Bone Loss and Improves Metabolic Disturbance in Estrogen-Deficient Rats.
Article in Pharmacology research & perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Carbohydrate-Rich Fraction of Aloe vera (L.) Burm.f. Extract Mitigates Bone Loss and Improves Metabolic Disturbance in Estrogen-Deficient Rats.Pharmacology research & perspectives · 2025Article
- The green healer: an updated review on the phytochemical profile and therapeutic potential ofFrontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Aloe vera (L.) Burm.f., (AE) herb has been shown to have osteogenic, anti-diabetic, and prebiotic activities in animal and human studies. Postmenopausal women generally exhibit massive bone loss, impaired intestinal calcium absorption, obesity-related insulin resistance, and fat accumulation in the liver. It was possible that the AE herb may have a potential as a remedy for bone and metabolic disturbances associated with estrogen deficiency. Sham and ovariectomized rats were divided into 2 subgroups, that is, receiving daily administration of distilled water or 50 or 100 mg/kg of AE via either oral administration (p.o.) or intraperitoneal injection (i.p.) for 8 and 12 weeks. Nine weeks after ovariectomy, rats developed metabolic disturbances, as evidenced by obesity, impaired glucose tolerance, and high serum cholesterol levels. AE supplementation, either by p.o. or i.p., alleviated metabolic aberrations by improving glucose tolerance, reducing body weight, and decreasing fat deposition by increasing serum insulin levels. Furthermore, AE supplementation restored ovariectomy-associated calcium malabsorption to that of sham. At week 12 post-ovariectomy, massive bone loss was observed at trabecular-rich regions. Daily AE supplementation at 50 mg/kg for 12 weeks, but not 8 weeks, significantly increased BMD and BMC compared with those of sham. Additionally, AE enhanced bone formation and suppressed bone resorption, as shown by bone histomorphometry and serum bone turnover markers. These findings clearly demonstrated the anti-diabetic and osteogenic properties of Aloe vera extract in ovariectomized rats. Thus, Aloe vera had a potential as a nutraceutical candidate for the treatment of osteoporosis and metabolic disturbances associated with estrogen deficiency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.